MedTrace Logo

Moderate Hypofractionated Radiotherapy for Lung Cancer

NCT03833193 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-03-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the incidences of Grade III and above radiation-reduced esophagitis and radiation-reduced pneumonia of patients with advanced lung cancer treated with moderate hypofractionated (3Gy/f) radiotherapy, and their predictors. Efficacies are also evaluated.

Conditions

Interventions

RADIATION

Hypofractionated radiotherapy

Radiation: Hypofractionated radiotherapy at 3Gy/f

Sponsors & Collaborators

  • North China Petroleum Bureau General Hospital

    lead OTHER

Principal Investigators

  • QIANG LIN, Dr · North China Petroleum Bureau General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-01
Primary Completion
2024-05-01
Completion
2025-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03833193 on ClinicalTrials.gov